Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa (GREENFIELD)

Trial Profile

Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa (GREENFIELD)

Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2018

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms GREENFIELD
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 16 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 16 Nov 2014 Planned End Date changed from 1 Feb 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top